drugset / Trial / NCT07555938
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the efficacy and safety of cevostamab in combination with pomalidomide and dexamethasone (CevosPd) versus standard of care (SOC) in participants with multiple myeloma (MM) who have received one to three prior lines of therapy and have been exposed to an anti-CD38 monoclonal antibody (mAb) and lenalidomide.
Timeline
- Start
- 2026-06-23
- Primary completion
- 2028-10-31
- Completion
- 2033-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Carfilzomib | Other / unclassified | — | Intravenous |
| Subject | Cevostamab | Monoclonal antibody | — | Intravenous |
| Comparator | Daratumumab | Monoclonal antibody | — | Subcutaneous |
| Comparator | Elotuzumab | Monoclonal antibody | — | Intravenous |
| Background | Dexamethasone | Small molecule | — | Oral |
| Background | Pomalidomide | Other / unclassified | — | Oral |